Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 9Neoplasms 4Neoplasm Metastasis 4Multiple Myeloma 4Gastrointestinal Stromal Tumors 4Thyroid Neoplasms 2Pancreatic Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma 2Kidney Neoplasms 2Gastrointestinal Neoplasms 2Carcinoma, Hepatocellular 2Carcinoma 2Adenoma, Islet Cell 2Uveal Melanoma 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urinary Bladder Neoplasms 1Thymoma 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Osteosarcoma 1Neuroendocrine Tumors 1Neoplasms by Site 1Metastatic Digestive System Neuroendocrine Tumor G1 1Meningioma 1

Interventions

spartalizumab 1pembrolizumab 1aldesleukin 1Sunitinib 1Interleukin-2 1Blood Specimen Collection 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Kidney Diseases × Sunitinib × 90 days × Clear all
NCT03091192 2026-04-14

Savolitinib vs. Sunitinib in MET-driven PRCC.

AstraZeneca

Phase 3 Active not recruiting
60 enrolled 15 charts
Genitourinary

Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms by Site, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡